Tonix2.jpg
Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences
March 09, 2021 07:30 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix2.jpg
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 04, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has...
Tonix2.jpg
Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)
February 11, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
Expands Proprietary Uses of Tonix’s Potentiated Oxytocin for Intranasal Administration Disorder Stunts Growth of Newborns and, Paradoxically, Can Cause Excessive Hunger During Childhood and Beyond ...
Tonix2.jpg
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
February 10, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix2.jpg
Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
February 09, 2021 16:05 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the...
Tonix2.jpg
Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
February 08, 2021 10:30 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has...
Tonix2.jpg
Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
February 08, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
Pre-IND Meeting Written Response from FDA Provides Guidance on Product Development and Clinical Testing Protocol Intradermal Test is Designed to Measure SARS-CoV-2 Specific Delayed Type...
Tonix2.jpg
Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions
January 14, 2021 07:00 ET | Tonix Pharmaceuticals Holding Corp.
GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021 CHATHAM, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the...
Tonix2.jpg
Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules
January 13, 2021 16:05 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the...
Tonix2.jpg
Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules
January 11, 2021 12:59 ET | Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has...